On August 14, 2025 Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, reported that it will host a virtual R&D Day on Tuesday, 19 August 2025 at 4 p.m. CEST (Press release, Alligator Bioscience, AUG 14, 2025, View Source [SID1234655280]). The event will provide an in-depth update on Alligator’s R&D pipeline, with a primary focus on its lead candidate mitazalimab, ahead of the upcoming TO 13 warrant exercise period (1–15 September 2025).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the event, members of Alligator’s executive management and R&D leadership will:
Provide update on mitazalimab clinical data, as well biomarker findings and Phase 3 readiness.
Discuss ongoing and planned investigator-initiated trials (IITs) exploring mitazalimab in additional indications and clinical settings.
Provide a brief update on the pipeline program HLX22.
Outline key R&D milestones over the next 6–12 months.
The R&D Day will be held as a live Teams webinar and will include a Q&A session. All participants will have the opportunity to submit questions in advance, via [email protected], or during the event.
Event details
Date: Tuesday, 19 August 2025
Time: 4-5 p.m. CEST
Format: Virtual Teams webinar
Registration: Please use this link to register
A replay of the event will be made available on Alligator’s website after the webinar.